



ADVANSOURCE BIOMATERIALS FILES PATENT FOR SILICONE-URETHANE COPOLYMERS

PATENT APPLICATION RELATES TO NEW CHRONOSIL™ PRODUCT

Wilmington, MA. November 5, 2009... AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced the recent filing of a patent for its newly launched ChronoSil polymer product, a silicone-urethane copolymer. This patent application relates to silicone-urethane copolymers and methods for making ChronoSil. ChronoSil can have many physical properties which are usually associated with polyurethanes, but also the feel and characteristics of silicones.

The ChronoSil product family maintains the inherent benefits of a polycarbonate-based urethane, including high pressure resistance, tensile-strength and superior chemical resistance combined with silicone's industry-recognized advantages such as heightened elongation, superior elasticity and a low coefficient of friction.

Michael Adams, President and CEO, stated, "We were pleased to announce our new biomaterial product, ChronoSil, a thermoplastic silicone polycarbonate urethane, which was exhibited at the recent MEDTEC IRELAND Medical Design and Manufacturing Exhibition and Conference in Galway, Ireland. Two of the objectives that are key to our business strategy include the development of innovative biomaterials to meet the needs of medical device developers and manufacturers while building additional value through a growing portfolio of patented products. This recent patent application supports our commitment to both of these objectives. We are pleased with the efforts of our research and development team and look forward to continued innovation from this talented group of scientists and engineers."

About AdvanSource Biomaterials Corporation

AdvanSource Biomaterials Corporation manufactures advanced polymer materials which provide critical characteristics in the design and development of medical devices. The Company's biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. AdvanSource's business model leverages its proprietary materials science technology and manufacturing expertise in order to expand its product sales and royalty and license fee income. More information about AdvanSource is available at its website: www.advbiomaterials.com

Forward-Looking Statements

AdvanSource believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forward-looking statements. For further information on such risks and uncertainties, you are encouraged to review AdvanSource's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended March 31, 2009 and its Quarterly Report on Form



10-Q for the quarter ended June 30, 2009. AdvanSource assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.

For further information contact:

AdvanSource Biomaterials Corporation

David Volpe, Acting CFO

(978) 657-0075, ext. 103

dvolpe@advbiomaterials.com